Abstract:Antigen delivery through an oral route requires overcoming multiple challenges, including gastrointestinal enzymes, mucus, and epithelial tight junctions. Although each barrier has a crucial role in determining the final efficiency of the oral vaccination, transcytosis of antigens through follicle-associated epithelium (FAE) represents a major challenge. Most of the research is focused on delivering an antigen to the M-cell for FAE transcytosis because M-cells can easily transport the antigen from the luminal site. However, the fact is that the M-cell population is less than 1% of the total gastrointestinal cells, and most of the oral vaccines have failed to show any effect in clinical trials. To challenge the current dogma of M-cell targeting, in this study, we designed a novel tandem peptide with a FAE-targeting peptide at the front position and a cell-penetrating peptide at the back position. The tandem peptide was attached to a smart delivery system, which overcomes the enzymatic barrier and the mucosal barrier. The result showed that the engineered system could target the FAE (enterocytes and M-cells) and successfully penetrate the enterocytes to reach the dendritic cells located at the subepithelium dome. There was successful maturation and activation of dendritic cells in vitro confirmed by a significant increase in maturation markers such as CD40, CD86, presentation marker MHC I, and proinflammatory cytokines (TNF-α, IL-6, and IL-10). The in vivo results showed a high production of CD4+ T-lymphocytes (helper T-cell) and a significantly higher production of CD8+ T-lymphocytes (killer T-cell). Finally, the production of mucosal immunity (IgA) in the trachea, intestine, and fecal extracts and systemic immunity (IgG, IgG1, and IgG2a) was successfully confirmed. To the best of our knowledge, this is the first study that designed a novel tandem peptide to target the FAE, which includes M-cells and enterocytes rather than M-cell targeting and showed that a significant induction of both the mucosal and systemic immune response was achieved compared to M-cell targeting.

Oral Immunization of FMDV Vaccine Using Ph-Sensitive and Mucoadhesive Thiolated Cellulose Acetate Phthalate Microparticles

A Novel Mucosal Vaccine Against Foot-and-Mouth Disease Virus Induces Protection in Mice and Swine

Enhancement of Serological Immune Responses to Foot-And-Mouth Disease Vaccine by A Supplement Made of Extract of Cochinchina Momordica Seeds

Improved neutralising antibody response against foot-and-mouth-disease virus in mice inoculated with a multi-epitope peptide vaccine using polyinosinic and poly-cytidylic acid as an adjuvant.

Promotion of Cellular and Humoral Immunity against Foot-and-Mouth Disease Virus by Immunization with Virus-Like Particles Encapsulated in Monophosphoryl Lipid A and Liposomes

Resiquimod and Polyinosinic–polycytidylic Acid Formulation with Aluminum Hydroxide As an Adjuvant for Foot-and-mouth Disease Vaccine

Poly(I:C) Combined with Multi-Epitope Protein Vaccine Completely Protects Against Virulent Foot-and-mouth Disease Virus Challenge in Pigs

Oral immunization against foot-and-mouth disease virus using recombinant Saccharomyces cerevisiae with the improved expression of the codon-optimized VP1 fusion protein

Double synergic chitosan-coated poly (lactic-co-glycolic) acid nanospheres loaded with nucleic acids as an intranasally administered vaccine delivery system to control the infection of foot-and-mouth disease virus

Synthesis of Empty Capsid-Like Particles of Asia I Foot-And-Mouth Disease Virus in Insect Cells and Their Immunogenicity in Guinea Pigs

Protection of Guinea Pigs and Swine by a Recombinant Adenovirus Expressing O Serotype of Foot-and-mouth Disease Virus Whole Capsid and 3C Protease.

Immune responses generated by Lactobacillus as a carrier in DNA immunization against foot-and-mouth disease virus.

Preparation of a Polysaccharide Adjuvant and Its Application in the Production of a Foot-and-mouth Disease Virus-Like Particles Vaccine

The C3d-fused foot-and-mouth disease vaccine platform overcomes maternally-derived antibody interference by inducing a potent adaptive immunity

Potent immune responses against thermostable Foot-and-Mouth disease virus VP1 nanovaccine adjuvanted with polymeric thermostable scaffold

Oral Administration of Zinc Sulfate with Intramuscular Foot-and-Mouth Disease Vaccine Enhances Mucosal and Systemic Immunity

Efficacy of a Novel Multiepitope Vaccine Candidate against Foot-and-Mouth Disease Virus Serotype O and A

Evaluation of a Vaccine Candidate Designed for Broad-Spectrum Protection against Type A Foot-and-Mouth Disease in Asia

Interleukin-15 Enhance DNA Vaccine Elicited Mucosal and Systemic Immunity Against Foot and Mouth Disease Virus

Engineered Nanoparticles inside a Microparticle Oral System for Enhanced Mucosal and Systemic Immunity

Dendritic cell-based biomimetic nanoparticles for foot-and-mouth disease induce robust cellular immunity